Displaying drugs 6851 - 6875 of 8235 in total
Etaracizumab
Etaracizumab has been investigated for the treatment of Psoriasis, Renal Cell Carcinoma, Stage IV Renal Cell Cancer, Recurrent Renal Cell Cancer, and Stage III Renal Cell Cancer.
Investigational
Matched Description: … Etaracizumab has been investigated for the treatment of Psoriasis, Renal Cell Carcinoma, Stage IV Renal …
Bavisant
Bavisant has been used in trials studying the basic science and treatment of Alcoholism, Pharmacokinetics, Drug Interactions, Attention Deficit Hyperactivity Disorder, and Attention Deficit Disorders With Hyperactivity.
Investigational
Matched Description: … Bavisant has been used in trials studying the basic science and treatment of Alcoholism, Pharmacokinetics …
GSK-356278
Gsk356278 has been used in trials studying the treatment and basic science of Anxiety Disorders, Huntington Disease, Depressive Disorder, Huntingtons Disease, and Depressive Disorder, Major, among others.
Investigational
Matched Description: … Gsk356278 has been used in trials studying the treatment and basic science of Anxiety Disorders, Huntington …
JNJ-42396302
Jnj 42396302 is under investigation in clinical trial NCT01732237 (A Study to Investigate the Pharmacokinetics of JNJ-42396302, JNJ-53773187 and JNJ-42692507 in Healthy Male Participants).
Investigational
Matched Description: … 42396302 is under investigation in clinical trial NCT01732237 (A Study to Investigate the Pharmacokinetics of …
Reposal
Reposal is a barbiturate derivative invented in the 1960s in Denmark that has sedative, hypnotic and anticonvulsant properties. It was used primarily in the treatment of insomnia.
Experimental
Matched Description: … It was used primarily in the treatment of insomnia. …
AZD-4017
AZD-4017 is under investigation in clinical trial NCT01173471 (A Phase IIa Study to Assess the Tolerability, Safety, and Efficacy of AZD4017 for Raised Intra-ocular Pressure).
Investigational
Matched Description: … investigation in clinical trial NCT01173471 (A Phase IIa Study to Assess the Tolerability, Safety, and Efficacy of …
Difamilast
Difamilast is under investigation in clinical trial NCT01702181 (A Safety Study to Evaluate the Use and Effectiveness of a Topical Ointment to Treat Adults With Atopic Dermatitis).
Investigational
Matched Description: … under investigation in clinical trial NCT01702181 (A Safety Study to Evaluate the Use and Effectiveness of …
LSZ-102
LSZ-102 is under investigation in clinical trial NCT02734615 (Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers).
Investigational
Matched Description: … LSZ-102 is under investigation in clinical trial NCT02734615 (Phase I/Ib Trial of LSZ102 Single Agent …
Elenbecestat
Elenbecestat is under investigation in clinical trial NCT02956486 (A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease).
Investigational
Matched Description: … under investigation in clinical trial NCT02956486 (A 24-Month Study to Evaluate the Efficacy and Safety of …
Brivoligide
Brivoligide is under investigation in clinical trial NCT04104919 (Study to Evaluate a Preop Dose of Brivoligide Injection for Pain After Mastectomy in Patients With High PCS Scores).
Investigational
Matched Description: … Brivoligide is under investigation in clinical trial NCT04104919 (Study to Evaluate a Preop Dose of Brivoligide …
Birtamimab
Birtamimab is under investigation in clinical trial NCT02312206 (The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis).
Investigational
Matched Description: … clinical trial NCT02312206 (The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of …
Ordesekimab
Ordesekimab is under investigation in clinical trial NCT02633020 (Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Type II Refractory Celiac Disease).
Investigational
Matched Description: … Ordesekimab is under investigation in clinical trial NCT02633020 (Study to Evaluate the Efficacy and Safety of …
JLK-247
JLK-247 is an adeno-associated viral vector serotype 9 (AAV9)-mediated gene replacement therapy for the treatment of Sanfilippo Syndrome Type C or MPS IIIC.
Investigational
Matched Description: … adeno-associated viral vector serotype 9 (AAV9)-mediated gene replacement therapy for the treatment of …
AGA2115
AGA2115 is a humanized bispecific antibody neutralizing both sclerostin and Dickkopf-1. Developed by Angitia Biopharmaceuticals, AGA2115 is being investigated for the treatment of osteogenesis imperfect.
Investigational
Matched Description: … Developed by Angitia Biopharmaceuticals, AGA2115 is being investigated for the treatment of osteogenesis …
Skin-derived ABCB5-positive Mesenchymal Stem cells
Skin-derived ABCB5-positive Mesenchymal Stem cells are under investigation in clinical trial NCT04971161 (Allogeneic Abcb5-positive Dermal Mesenchymal Stromal Cells for Treatment of CVU (Phase Iib)).
Investigational
Matched Description: … clinical trial NCT04971161 (Allogeneic Abcb5-positive Dermal Mesenchymal Stromal Cells for Treatment of …
PAS-004
PAS-004 is an allosteric MEK 1/2 inhibitor being developed by Pasithea Therapeutics. It is being investigated for the treatment of neurofibromatosis 1 and Noonan syndrome.
Investigational
Matched Description: … It is being investigated for the treatment of neurofibromatosis 1 and Noonan syndrome. …
Socazolimab
Socazolimab is under investigation in clinical trial NCT04878016 (A Study of Carboplatin Plus Etoposide With or Without ZKAB001 (Anti-pd-l1 Antibody) in Patients With ES-SCLC).
Investigational
Matched Description: … Socazolimab is under investigation in clinical trial NCT04878016 (A Study of Carboplatin Plus Etoposide …
Plutavimab
Plutavimab is under investigation in clinical trial NCT04900428 (Study to Evaluate a Single Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With COVID-19 (UK)).
Investigational
Matched Description: … Plutavimab is under investigation in clinical trial NCT04900428 (Study to Evaluate a Single Intranasal Dose of …
JNJ-39758979
JNJ-39758979 is under investigation in clinical trial NCT01480388 (A Dose Range Finding Study of JNJ-39758979 in Patients With Active Rheumatoid Arthritis Currently Treated With Methotrexate).
Investigational
Matched Description: … JNJ-39758979 is under investigation in clinical trial NCT01480388 (A Dose Range Finding Study of JNJ- …
Befiradol
Befiradol is under investigation in clinical trial NCT05148884 (Study to Assess the Safety, Tolerability and Preliminary Efficacy of NLX-112 Versus Placebo in L-dopa-induced Dyskinesia).
Investigational
Matched Description: … investigation in clinical trial NCT05148884 (Study to Assess the Safety, Tolerability and Preliminary Efficacy of …
KRN-330
Anti-a33 fully-human monoclonal antibody is under investigation in clinical trial NCT00838578 (Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer).
Investigational
Matched Description: … fully-human monoclonal antibody is under investigation in clinical trial NCT00838578 (Phase I/II Study of …
9-amino-n-[3-(dimethylamino)propyl]acridine-4-carboxamide
9-amino-n-[3-(dimethylamino)propyl]acridine-4-carboxamide is an inactive derivative of the antitumour agents N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA) and 9-amino-DACA.
Experimental
Matched Description: … 9-amino-n-[3-(dimethylamino)propyl]acridine-4-carboxamide is an inactive derivative of the antitumour …
Peptide YY (3-36)
Peptide YY (3-36), a synthetic human PYY 3-36, is a compound being evaluated for the treatment of obesity. It reduces appetite and increases satiety in obese patients.
Investigational
Matched Description: … Peptide YY (3-36), a synthetic human PYY 3-36, is a compound being evaluated for the treatment of obesity …
PM02734
PM02734 is a marine derived compound. PM02734 as a new antiproliferative drug demonstrating activity against a broad spectrum of tumor types: breast, colon, pancreas, lung and prostate, among others.
Investigational
Matched Description: … PM02734 as a new antiproliferative drug demonstrating activity against a broad spectrum of tumor types …
Caprospinol
Caprospinol (SP-233) is the first drug ever to demonstrate the correlation of clearing beta-amyloid from the brain. It also improves the brain histopathology and recovers memory function.
Investigational
Matched Description: … Caprospinol (SP-233) is the first drug ever to demonstrate the correlation of clearing beta-amyloid from …
Displaying drugs 6851 - 6875 of 8235 in total